정밀 바이오틱스 시장 예측(-2031년) : 예측 유형(정밀 프로바이오틱스, 차세대 프로바이오틱스, 신바이오틱스, 포스트바이오틱스), 최종사용자 산업, 건강 및 기능성 포지셔닝, 유통 채널, 지역별

The precision biotics market is estimated to record USD 4.91 billion in 2026 and reach USD 9.26 billion by 2031, at a CAGR of 13.5% from 2026 to 2031.

"Gut & brain segment is driving market growth due to the rising focus on the gut-brain axis and personalized mental wellness solutions"

The gut & brain sub-segment under health/functional positioning is expected to witness the fastest growth in the precision biotics market owing to the growing awareness about the gut-brain axis and rising cases of stress, anxiety, depression, and other mental conditions. The ongoing developments in microbiome science, growing scientific evidence of the impact of gut microbiota on brain function, and the need for tailored solutions for improving mental wellness are leading to the rising use of precision biotics for gut and brain health.

"E-commerce is driving market growth through expanding online retail and digital health platforms"

E-commerce is expected to become the fastest-growing route for distribution within the precision biotics market owing to the rising online purchasing trends and consumers' growing inclination toward easily available precision biotics products online. The development of online pharmacies, health and wellness platforms, as well as personalized offerings and recommendations, makes precision biotics more readily available, while competitive prices, broad product availability, and delivery at home keep boosting sales online.

"North America is expected to hold a significant share in the global precision biotics market owing to its advanced microbiome research ecosystem & strong industry presence"

North America holds the major share in the precision biotics market owing to the well-developed research ecosystem for microbiome, the presence of prominent precision biotics firms, and the use of personalized nutrition and preventive healthcare. Some other factors that contribute to the success of North America include the established healthcare infrastructure, rising awareness among consumers about gut health, innovations in microbiome, and access to clinically tested precision biotics.

In-depth interviews have been conducted with chief executive officers (CEOs), directors, and other executives from various key organizations operating in the Precision Biotics market.

• By Company Type: Tier 1 - 30%, Tier 2 - 25%, and Tier 3 - 45%
• By Designation: CXOs - 25%, Managers - 35%, Others - 40%
• By Region: North America - 20%, Europe - 30%, Asia Pacific - 35%, and Rest of the World - 5%

Prominent companies in the market include BioGaia (Sweden), Novonesis Group (Denmark), Procter & Gamble (US), Unilever (UK), dsm-firmenich (Switzerland), Metagenics, LLC (US), Yakult Honsha Co., Ltd (Japan), Danone (France), KANEKA CORPORATION (Japan), Symrise (Germany)- (Probi), Jarrow Formulas, Inc (US), Pendulum (US), thegoodbug (India), Seed Health, Inc (US), Infinant Health Inc (US), and others.

Research Coverage

This research report categorizes the precision biotics market by type (precision probiotics, next generation probiotics (NGPs), synbiotics, postbiotics), end-use industry (dietary supplements, functional food & beverages, pet supplements, pharmaceutical (OTC), infant formula, cosmetics, animal feed), health/functional positioning (digestive & gastrointestinal health, women's health, pediatric & infant health, skin health, gut & brain health, metabolic health, immune health, oral & dental health), distribution channel (pharmacies, retail, specialty stores, e-commerce, DTC subscription platforms), and region (North America, Europe, Asia Pacific, Rest of the World).

The report's scope encompasses detailed information on the major factors, including drivers, restraints, challenges, and opportunities, that influence the growth of the Precision Biotics industry. A thorough analysis of the key industry players has been done to provide insights into their business, services, key strategies, contracts, partnerships, agreements, product launches, mergers & acquisitions, and recent developments associated with the Precision Biotics market. This report provides a competitive analysis of emerging startups in the Precision Biotics market ecosystem. Furthermore, the study covers industry-specific trends, including technology analysis, ecosystem & market mapping, and patent & regulatory landscape, among others.

Reasons to Buy This Report

The report provides market leaders/new entrants with information on the closest approximations of revenue numbers for the overall precision biotics and its subsegments. It will help stakeholders understand the competitive landscape and gain more insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.

The report provides insights into the following pointers:

• Analysis of key drivers (Growing Adoption of Personalized & Targeted Nutrition and Microbiome-based Healthcare, Growing Incidence of Gastrointestinal Disorders), restraints (High Development Costs of Strain-Specific Precision Biotics, Complex Regulatory Pathways for Personalized Microbiome Products), opportunities (Increasing Partnerships Between Biotech Firms and Healthcare Providers, Rising Demand for Precision Nutrition in Chronic Disease Management), and challenges (Ensuring Strain Stability and Product Quality Across Supply Chains, Need for Robust Clinical Evidence to Support Health Claims)
• Product Development/Innovation: Detailed insights into research & development activities and product launches in the precision biotics market
• Market Development: Comprehensive information about lucrative markets-analysis of precision biotics across varied regions
• Market Diversification: Exhaustive information about product sources, untapped geographies, recent developments, and investments in the precision biotics market
• Competitive Assessment: In depth assessment of market shares, growth strategies, product offerings, brand/product comparison, and product footprints of leading players such as Darling Ingredients (US), Tessenderlo Group (Belgium) - BioGaia (Sweden), Novonesis Group (Denmark), Procter & Gamble (US), Unilever (UK), dsm-firmenich (Switzerland), Metagenics, LLC (US), Yakult Honsha Co., Ltd (Japan), Danone (France), KANEKA CORPORATION (Japan), Symrise (Germany)-(Probi), Jarrow Formulas, Inc (US), Pendulum (US), thegoodbug (India), Seed Health, Inc (US), Infinant Health Inc (US), and other players in the precision biotics market.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE AND SEGMENTATION
  • 1.3.1 YEARS CONSIDERED
  • 1.3.2 CURRENCY CONSIDERED
  • 1.3.3 UNIT CONSIDERED
• 1.4 STAKEHOLDERS

2 EXECUTIVE SUMMARY

• 2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS
• 2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS
• 2.3 DISRUPTIVE TRENDS IN PRECISION BIOTICS MARKET
• 2.4 HIGH-GROWTH SEGMENTS
• 2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST

3 PREMIUM INSIGHTS

• 3.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN PRECISION BIOTICS MARKET
• 3.2 PRECISION BIOTICS MARKET, BY TYPE AND REGION
• 3.3 PRECISION BIOTICS MARKET, BY TOP THREE TYPES
• 3.4 PRECISION BIOTICS MARKET, BY DISTRIBUTION CHANNEL
• 3.5 PRECISION BIOTICS MARKET, BY TOP FOUR HEALTH/ FUNCTIONAL POSITIONINGS
• 3.6 PRECISION BIOTICS MARKET, BY END-USE INDUSTRY
• 3.7 PRECISION BIOTICS MARKET, BY COUNTRY

4 MARKET OVERVIEW

• 4.1 INTRODUCTION
• 4.2 MARKET DYNAMICS
  • 4.2.1 DRIVERS
    • 4.2.1.1 Growing adoption of personalized & targeted nutrition and microbiome-based healthcare
    • 4.2.1.2 Growing incidence of gastrointestinal disorders
    • 4.2.1.3 Growing consumer focus on preventive healthcare
  • 4.2.2 RESTRAINTS
    • 4.2.2.1 High development costs of strain-specific precision biotics
    • 4.2.2.2 Complex regulatory pathways for personalized microbiome products
  • 4.2.3 OPPORTUNITIES
    • 4.2.3.1 Increasing partnerships between biotech firms and healthcare providers
    • 4.2.3.2 Rising demand for precision nutrition in chronic disease management
    • 4.2.3.3 Growing integration of AI and multi-omics technologies in product development & advancement in the microbiome sequencing
  • 4.2.4 CHALLENGES
    • 4.2.4.1 Ensuring strain stability and product quality across supply chains
    • 4.2.4.2 Need for robust clinical evidence to support health claims
• 4.3 UNMET NEEDS AND WHITE SPACES
  • 4.3.1 UNMET NEEDS IN PRECISION BIOTICS MARKET
  • 4.3.2 WHITE SPACE OPPORTUNITIES
• 4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
  • 4.4.1 INTERCONNECTED MARKETS
  • 4.4.2 CROSS-SECTOR OPPORTUNITIES
• 4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
  • 4.5.1 KEY MOVES AND STRATEGIC FOCUS

5 INDUSTRY TRENDS

• 5.1 PORTER'S FIVE FORCES ANALYSIS
  • 5.1.1 INTENSITY OF COMPETITIVE RIVALRY
  • 5.1.2 BARGAINING POWER OF SUPPLIERS
  • 5.1.3 BARGAINING POWER OF BUYERS
  • 5.1.4 THREAT OF SUBSTITUTES
  • 5.1.5 THREAT OF NEW ENTRANTS
• 5.2 MACROECONOMIC OUTLOOK
  • 5.2.1 INTRODUCTION
  • 5.2.2 MACROECONOMIC INDICATORS
    • 5.2.2.1 Aging demographics fuel growth of north american probiotics market
    • 5.2.2.2 Increasing national healthcare expenditure
    • 5.2.2.3 Increasing prevalence of lifestyle-related chronic disorders
• 5.3 VALUE CHAIN ANALYSIS
  • 5.3.1 RESEARCH & CONSUMER PRODUCT DEVELOPMENT
  • 5.3.2 INGREDIENT SOURCING & STRAIN DEVELOPMENT
  • 5.3.3 MANUFACTURING & PRODUCT FORMULATION
  • 5.3.4 DISTRIBUTION, RETAIL & SUPPLY CHAIN MANAGEMENT
  • 5.3.5 CONSUMER APPLICATIONS & COMMERCIALIZATION
• 5.4 ECOSYSTEM/MARKET MAP ANALYSES
  • 5.4.1 DEMAND SIDE
  • 5.4.2 SUPPLY SIDE
• 5.5 PRICING ANALYSIS
  • 5.5.1 INTRODUCTION
  • 5.5.2 INDICATIVE PRICE TREND AMONG MARKET PLAYERS
  • 5.5.3 AVERAGE SELLING PRICE (ASP) TREND, BY REGION
  • 5.5.4 AVERAGE SELLING PRICE (ASP) TREND BY TYPE, 2022-2025 (USD/TONS)
• 5.6 TRADE ANALYSIS
  • 5.6.1 IMPORT ANALYSIS: PRECISION BIOTICS
  • 5.6.2 EXPORT ANALYSIS: PRECISION BIOTICS
• 5.7 KEY CONFERENCES AND EVENTS, 2026-2027
• 5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.9 INVESTMENT AND FUNDING SCENARIO
• 5.10 CASE STUDY ANALYSIS
  • 5.10.1 PENDULUM - LAUNCH OF PENDULUM GLUCOSE CONTROL FOR PRECISION BLOOD SUGAR MANAGEMENT
  • 5.10.2 BIOGAIA - LAUNCH OF BIOGAIA PROTECTIS PLUS NEXT-GENERATION PATENTED PROBIOTIC DROPS
  • 5.10.3 FLORE (SUN GENOMICS) - DEVELOPMENT OF PRECISION SYNBIOTICS FOR AUTISM SPECTRUM DISORDER SUPPORT
  • 5.10.4 VIOME - LAUNCH OF VRX MY**BIOTICS TOOTHPASTE & GEL FOR PERSONALIZED ORAL MICROBIOME HEALTH
• 5.11 IMPACT OF 2025 US TARIFF -PRECISION BIOTICS MARKET
  • 5.11.1 INTRODUCTION
  • 5.11.2 PRICE IMPACT ANALYSIS
  • 5.11.3 IMPACT ON COUNTRIES/REGIONS
    • 5.11.3.1 US
    • 5.11.3.2 Europe
    • 5.11.3.3 Asia Pacific
  • 5.11.4 IMPACT ON END USE INDUSTRIES

6 TECHNOLOGY ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS

• 6.1 TECHNOLOGY ANALYSIS
  • 6.1.1 KEY TECHNOLOGIES
    • 6.1.1.1 Next-generation sequencing (NGS)
    • 6.1.1.2 Precision fermentation & strain engineering
  • 6.1.2 COMPLEMENTARY ANALYSIS
    • 6.1.2.1 Microencapsulation & controlled release delivery systems
    • 6.1.2.2 Synbiotic formulation technologies
  • 6.1.3 ADJACENT TECHNOLOGIES
    • 6.1.3.1 Bioprocess automation & smart manufacturing
    • 6.1.3.2 Metabolomics platforms
• 6.2 PATENT ANALYSIS
• 6.3 FUTURE APPLICATIONS
  • 6.3.1 SMART (DISEASE-SENSING) PROBIOTICS: ENABLING THE NEXT GENERATION OF PRECISION BIOTICS
  • 6.3.2 ENGINEERED LIVE BIOTHERAPEUTICS: SHAPING THE FUTURE OF PRECISION BIOTICS
  • 6.3.3 ENGINEERED PRECISION PROBIOTICS FOR INFLAMMATORY BOWEL DISEASE (IBD): ADVANCING TARGETED MICROBIOME THERAPEUTICS
  • 6.3.4 POSTBIOTICS FOR NEXT-GENERATION FUNCTIONAL FOODS AND BIOPRESERVATION
• 6.4 IMPACT OF GENERATIVE AI ON PRECISION BIOTICS MARKET
  • 6.4.1 INTRODUCTION
  • 6.4.2 TOP USE CASES AND MARKET POTENTIAL
  • 6.4.3 BEST PRACTICES IN PRECISION BIOTICS INDUSTRY
  • 6.4.4 CASE STUDIES OF AI IMPLEMENTATION IN THE PRECISION BIOTICS MARKET
  • 6.4.5 INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS
  • 6.4.6 CLIENTS' READINESS TO ADOPT GENERATIVE AI FOR PRECISION BIOTICS
• 6.5 SUCCESS STORIES AND REAL-WORLD APPLICATIONS

7 SUSTAINABILITY AND REGULATORY LANDSCAPE

• 7.1 REGIONAL REGULATIONS AND COMPLIANCE
  • 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 7.1.2 INDUSTRY STANDARDS
  • 7.1.3 LABELING REQUIREMENTS AND CLAIMS
  • 7.1.4 ANTICIPATED REGULATORY CHANGES IN NEXT 5-10 YEARS
    • 7.1.4.1 Enhanced strain traceability and clinical evidence requirements
    • 7.1.4.2 Global harmonization of precision biotics regulations
    • 7.1.4.3 Stricter clinical validation and health claim compliance
    • 7.1.4.4 Digital traceability, AI-enabled quality monitoring, and compliance automation
    • 7.1.4.5 Higher quality standards for live biotherapeutic and next-generation biotics
• 7.2 SUSTAINABILITY INITIATIVES
  • 7.2.1 SUSTAINABLE SOURCING
  • 7.2.2 CARBON FOOTPRINT REDUCTION INITIATIVES
  • 7.2.3 CIRCULAR ECONOMY APPROACHES
• 7.3 SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES
• 7.4 CERTIFICATIONS, LABELING, ECO-STANDARDS

8 CUSTOMER LANDSCAPE AND BUYER BEHAVIOR

• 8.1 DECISION-MAKING PROCESS
• 8.2 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 8.2.2 BUYING CRITERIA
• 8.3 ADOPTION BARRIERS AND INTERNAL CHALLENGES
• 8.4 UNMET NEEDS OF VARIOUS APPLICATION INDUSTRIES ACROSS SUPPLY CHAIN
• 8.5 MARKET PROFITABILITY
• 8.6 REVENUE POTENTIAL
  • 8.6.1 COST DYNAMICS
  • 8.6.2 MARGIN OPPORTUNITIES, BY TYPE

9 PRECISION BIOTICS MARKET, BY TYPE

• 9.1 INTRODUCTION
• 9.2 PRECISION PROBIOTICS
  • 9.2.1 PRECISION PROBIOTICS TO FUEL EXPANSION OF PRECISION BIOTICS MARKET
• 9.3 NEXT-GENERATION PROBIOTICS
  • 9.3.1 NEXT-GENERATION PROBIOTICS DRIVING INNOVATION IN PRECISION BIOTICS MARKET
• 9.4 SYNBIOTICS
  • 9.4.1 PERSONALIZED SYNBIOTICS DRIVING INNOVATION AND GROWTH IN PRECISION BIOTICS MARKET
• 9.5 POSTBIOTICS
  • 9.5.1 COMMERCIALIZATION OF POSTBIOTIC PRODUCTS STRENGTHENING PRECISION BIOTICS MARKET

10 PRECISION BIOTICS MARKET, BY END-USE INDUSTRY

• 10.1 INTRODUCTION
• 10.2 DIETARY SUPPLEMENTS
  • 10.2.1 GROWING DIETARY SUPPLEMENT ADOPTION DRIVING GLOBAL PRECISION BIOTICS GROWTH
• 10.3 FUNCTIONAL FOOD & BEVERAGES
  • 10.3.1 GROWING DEMAND FOR FUNCTIONAL FOODS DRIVING PRECISION BIOTICS ADOPTION
• 10.4 PET SUPPLEMENTS
  • 10.4.1 RISING PET HUMANIZATION DRIVING PRECISION BIOTICS ADOPTION IN COMPANION ANIMAL NUTRITION
• 10.5 PHARMACEUTICALS (OTC)
  • 10.5.1 GROWING OTC SELF-CARE TRENDS ACCELERATING PRECISION BIOTICS ADOPTION
• 10.6 INFANT FORMULA
  • 10.6.1 EARLY-LIFE NUTRITION INNOVATION DRIVING PRECISION BIOTICS ADOPTION IN INFANT FORMULA
• 10.7 COSMETICS
  • 10.7.1 GROWING INVESTMENT IN MICROBIOME-BASED BEAUTY DRIVING PRECISION BIOTICS ADOPTION
• 10.8 ANIMAL FEED
  • 10.8.1 SUSTAINABLE ANIMAL NUTRITION DRIVING PRECISION BIOTICS ADOPTION

11 PRECISION BIOTICS MARKET, BY DISTRIBUTION CHANNEL

• 11.1 INTRODUCTION
• 11.2 PHARMACIES
  • 11.2.1 PHARMACIES ACCELERATING ADOPTION OF PRECISION BIOTICS ACROSS GLOBE
• 11.3 RETAIL
  • 11.3.1 EXPANDING ORGANIZED RETAIL NETWORKS STRENGTHEN CONSUMER ACCESS TO PRECISION BIOTICS
• 11.4 SPECIALTY STORES
  • 11.4.1 SPECIALTY HEALTH STORES ENHANCE CONSUMER ACCESS TO PRECISION BIOTICS GLOBALLY
• 11.5 E-COMMERCE
  • 11.5.1 EXPANDING E-COMMERCE PLATFORMS ACCELERATE PRECISION BIOTICS ADOPTION GLOBALLY
• 11.6 DTC SUBSCRIPTION PLATFORMS
  • 11.6.1 DIRECT-TO-CONSUMER (DTC) SUBSCRIPTION PLATFORMS EXPAND GLOBAL PRECISION BIOTICS ACCESSIBILITY

12 PRECISION BIOTICS MARKET, BY HEALTH/ FUNCTIONAL POSITIONING

• 12.1 INTRODUCTION
• 12.2 DIGESTIVE & GASTROINTESTINAL HEALTH
  • 12.2.1 MICROBIOME-BASED DIGESTIVE & GASTROINTESTINAL HEALTH SOLUTIONS ACCELERATING MARKET GROWTH
• 12.3 WOMEN'S HEALTH
  • 12.3.1 ADVANCING WOMEN'S HEALTH THROUGH PRECISION MICROBIOME INNOVATION
• 12.4 PEDIATRIC & INFANT HEALTH
  • 12.4.1 PEDIATRIC & INFANT HEALTH DRIVING GROWTH OF PRECISION BIOTICS MARKET
• 12.5 SKIN HEALTH
  • 12.5.1 GROWING BURDEN OF SKIN DISORDERS DRIVING GLOBAL PRECISION BIOTICS ADOPTION
• 12.6 GUT & BRAIN HEALTH
  • 12.6.1 GROWING MENTAL HEALTH BURDEN ACCELERATING PRECISION BIOTICS ADOPTION THROUGH GUT-BRAIN AXIS
• 12.7 METABOLIC HEALTH
  • 12.7.1 GROWING BURDEN OF DIABETES AND PREDIABETES ACCELERATING PRECISION BIOTICS ADOPTION
• 12.8 IMMUNE HEALTH
  • 12.8.1 GROWING FOCUS ON PREVENTIVE IMMUNITY DRIVING GLOBAL PRECISION BIOTICS ADOPTION
• 12.9 ORAL & DENTAL HEALTH
  • 12.9.1 GROWING FOCUS ON PREVENTIVE IMMUNITY DRIVING GLOBAL PRECISION BIOTICS ADOPTION

13 PRECISION BIOTICS MARKET, BY REGION

• 13.1 INTRODUCTION
• 13.2 NORTH AMERICA
  • 13.2.1 US
    • 13.2.1.1 Growing government investments, precision nutrition initiatives, and strategic collaborations driving US precision biotics market
  • 13.2.2 CANADA
    • 13.2.2.1 Government investments, expanding genomics ecosystem and commercialization programs accelerating Canadian precision biotics market
• 13.3 EUROPE
  • 13.3.1 GERMANY
    • 13.3.1.1 Precision Biotics Market Driven by Clinical Research and Personalized Nutrition
  • 13.3.2 UK
    • 13.3.2.1 Increasing Burden of Gastrointestinal Disorders Fueling Precision Biotics Demand
  • 13.3.3 FRANCE
    • 13.3.3.1 Growing Consumer Awareness and Personalized Nutrition Supporting Precision Biotics
  • 13.3.4 ITALY
    • 13.3.4.1 Strong Dietary Supplement Adoption Accelerates Precision Biotics Market Growth in Italy
  • 13.3.5 SPAIN
    • 13.3.5.1 Growing precision medicine and microbiome research drive Spain's precision biotics market
  • 13.3.6 REST OF EUROPE
• 13.4 ASIA PACIFIC
  • 13.4.1 CHINA
    • 13.4.1.1 Expanding nutritional supplements industry accelerating precision biotics adoption in China
  • 13.4.2 INDIA
    • 13.4.2.1 Rising consumer awareness of gut health and preventive healthcare drives precision biotics market growth
  • 13.4.3 JAPAN
    • 13.4.3.1 Growing pharmaceutical investments support Japan's precision biotics market
  • 13.4.4 AUSTRALIA & NEW ZEALAND
    • 13.4.4.1 Advanced life sciences research and preventive healthcare drive the Australia & New Zealand precision biotics market
  • 13.4.5 REST OF ASIA PACIFIC
• 13.5 REST OF THE WORLD (ROW)
  • 13.5.1 LATIN AMERICA
    • 13.5.1.1 Rising obesity and metabolic disorders drive precision biotics market growth
  • 13.5.2 MIDDLE EAST
    • 13.5.2.1 Expanding pharmaceutical manufacturing and precision medicine drive precision biotics market growth
  • 13.5.3 AFRICA
    • 13.5.3.1 Rising awareness of gut health and personalized nutrition supports market growth

14 COMPETITIVE LANDSCAPE

• 14.1 OVERVIEW
• 14.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
• 14.3 REVENUE ANALYSIS, 2023-2025
• 14.4 MARKET SHARE ANALYSIS, 2025
• 14.5 COMPANY VALUATION AND FINANCIAL METRICS
  • 14.5.1 COMPANY VALUATION
  • 14.5.2 EV/EBITDA
• 14.6 BRAND COMPARISON ANALYSIS, BY TYPE
• 14.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
  • 14.7.1 STARS
  • 14.7.2 EMERGING LEADERS
  • 14.7.3 PERVASIVE PLAYERS
  • 14.7.4 PARTICIPANTS
  • 14.7.5 COMPANY FOOTPRINT: KEY PLAYERS
    • 14.7.5.1 Regional footprint
    • 14.7.5.2 Type footprint
    • 14.7.5.3 Function footprint
• 14.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
  • 14.8.1 PROGRESSIVE COMPANIES
  • 14.8.2 RESPONSIVE COMPANIES
  • 14.8.3 DYNAMIC COMPANIES
  • 14.8.4 STARTING BLOCKS
  • 14.8.5 COMPETITIVE BENCHMARKING: KEY STARTUPS/SMES, 2025
    • 14.8.5.1 Detailed list of key startups/SMEs
    • 14.8.5.2 Competitive benchmarking of key startups/SMEs
• 14.9 COMPETITIVE SCENARIO AND TRENDS
  • 14.9.1 PRODUCT LAUNCHES
  • 14.9.2 DEALS

15 COMPANY PROFILES

• 15.1 KEY PLAYERS
  • 15.1.1 BIOGAIA
    • 15.1.1.1 Business overview
    • 15.1.1.2 Products/Solutions/Services offered
    • 15.1.1.3 Recent developments
      • 15.1.1.3.1 Product launches
      • 15.1.1.3.2 Deals
    • 15.1.1.4 MnM view
      • 15.1.1.4.1 Key strengths
      • 15.1.1.4.2 Strategic choices
      • 15.1.1.4.3 Weaknesses & competitive threats
  • 15.1.2 NOVONESIS GROUP
    • 15.1.2.1 Business overview
    • 15.1.2.2 Products/Solutions/Services offered
    • 15.1.2.3 Recent developments
      • 15.1.2.3.1 Deals
    • 15.1.2.4 MnM view
      • 15.1.2.4.1 Key strengths
      • 15.1.2.4.2 Strategic choices
      • 15.1.2.4.3 Weaknesses & competitive threats
  • 15.1.3 PROCTER & GAMBLE
    • 15.1.3.1 Business overview
    • 15.1.3.2 Products/Solutions/Services offered
    • 15.1.3.3 MnM view
      • 15.1.3.3.1 Key strengths
      • 15.1.3.3.2 Strategic choices
      • 15.1.3.3.3 Weaknesses & competitive threats
  • 15.1.4 UNILEVER
    • 15.1.4.1 Business overview
    • 15.1.4.2 Products/Solutions/Services offered
    • 15.1.4.3 Recent developments
      • 15.1.4.3.1 Product launches
    • 15.1.4.4 MnM view
      • 15.1.4.4.1 Key strengths
      • 15.1.4.4.2 Strategic choices
      • 15.1.4.4.3 Weaknesses & competitive threats
  • 15.1.5 DSM-FIRMENICH GROUP (CULTURELLE)
    • 15.1.5.1 Business overview
    • 15.1.5.2 Products/Solutions/Services offered
      • 15.1.5.2.1 Deals
    • 15.1.5.3 MnM view
      • 15.1.5.3.1 Key strengths
      • 15.1.5.3.2 Strategic choices
      • 15.1.5.3.3 Weaknesses & competitive threats
  • 15.1.6 NESTLE (NESTLE HEALTH SCIENCE)
    • 15.1.6.1 Business overview
    • 15.1.6.2 Products/Solutions/Services offered
    • 15.1.6.3 MnM view
  • 15.1.7 METAGENICS, LLC
    • 15.1.7.1 Business overview
    • 15.1.7.2 Products/Solutions/Services offered
    • 15.1.7.3 Recent developments
      • 15.1.7.3.1 Deals
    • 15.1.7.4 MnM view
  • 15.1.8 YAKULT HONSHA CO., LTD.
    • 15.1.8.1 Business overview
    • 15.1.8.2 Products/Solutions/Services offered
    • 15.1.8.3 Recent developments
      • 15.1.8.3.1 Product launches
    • 15.1.8.4 MnM view
  • 15.1.9 DANONE
    • 15.1.9.1 Business overview
    • 15.1.9.2 Products/Solutions/Services offered
    • 15.1.9.3 Recent developments
      • 15.1.9.3.1 Deals
    • 15.1.9.4 MnM view
  • 15.1.10 KANEKA CORPORATION (AB-BIOTICS)
    • 15.1.10.1 Business overview
    • 15.1.10.2 Products/Solutions/Services offered
    • 15.1.10.3 Recent developments
      • 15.1.10.3.1 Product launches
    • 15.1.10.4 MnM view
  • 15.1.11 SYMRISE GROUP (PROBI): BUSINESS OVERVIEW
    • 15.1.11.1 Products/Solutions/Services offered
    • 15.1.11.2 MnM view
  • 15.1.12 JARROW FORMULAS, INC
    • 15.1.12.1 Business overview
    • 15.1.12.2 Products/Solutions/Services offered
    • 15.1.12.3 MnM view
  • 15.1.13 PENDULUM
    • 15.1.13.1 Business overview
    • 15.1.13.2 Products/Solutions/Services offered
    • 15.1.13.3 Recent developments
      • 15.1.13.3.1 Product launches
    • 15.1.13.4 MnM view
  • 15.1.14 THE GOOD BUG
    • 15.1.14.1 Business overview
    • 15.1.14.2 Products/Solutions/Services offered
    • 15.1.14.3 MnM view
  • 15.1.15 SEED HEALTH INC
    • 15.1.15.1 Business overview
    • 15.1.15.2 Products/Solutions/Services offered
    • 15.1.15.3 MnM view
• 15.2 OTHER PLAYERS
  • 15.2.1 INFINANT HEALTH INC.
    • 15.2.1.1 Business overview
    • 15.2.1.2 Products/Solutions/Services offered
    • 15.2.1.3 MnM view
  • 15.2.2 VIOME LIFE SCIENCES, INC.
    • 15.2.2.1 Business overview
    • 15.2.2.2 Products/Solutions/Services offered
      • 15.2.2.2.1 Product launches
    • 15.2.2.3 MnM view
  • 15.2.3 BLACKMORES
    • 15.2.3.1 Business overview
    • 15.2.3.2 Products/Solutions/Services offered
    • 15.2.3.3 MnM view
  • 15.2.4 LAYER ORIGIN NUTRITION
    • 15.2.4.1 Business overview
    • 15.2.4.2 Products/Solutions/Services offered
    • 15.2.4.3 Recent developments
    • 15.2.4.4 MnM view
  • 15.2.5 RESBIOTIC
    • 15.2.5.1 Business overview
    • 15.2.5.2 Products/Solutions/Services offered
    • 15.2.5.3 Recent developments
      • 15.2.5.3.1 Product launches
    • 15.2.5.4 MnM view
  • 15.2.6 FITBIOMICS
  • 15.2.7 FLORE INC
  • 15.2.8 ZBIOTICS
  • 15.2.9 BIOHM TECHNOLOGIES
  • 15.2.10 MRO MARYRUTH, LLC.

16 RESEARCH METHODOLOGY

• 16.1 RESEARCH DATA
  • 16.1.1 SECONDARY DATA
    • 16.1.1.1 Key data from secondary sources
  • 16.1.2 PRIMARY DATA
    • 16.1.2.1 Key data from primary sources
    • 16.1.2.2 Breakdown of primary profiles
    • 16.1.2.3 Key insights from industry experts
• 16.2 MARKET SIZE ESTIMATION
  • 16.2.1 TOP-DOWN APPROACH
  • 16.2.2 SUPPLY-SIDE ANALYSIS
  • 16.2.3 BOTTOM-UP APPROACH (DEMAND SIDE)
• 16.3 DATA TRIANGULATION AND MARKET BREAKUP
• 16.4 RESEARCH ASSUMPTIONS
• 16.5 RESEARCH LIMITATIONS AND RISK ASSESSMENT

17 ADJACENT AND RELATED MARKETS

• 17.1 INTRODUCTION
• 17.2 RESEARCH LIMITATIONS
• 17.3 PROBIOTIC SUPPLEMENTS MARKET
  • 17.3.1 MARKET DEFINITION
  • 17.3.2 MARKET OVERVIEW
• 17.4 PROBIOTICS MARKET
  • 17.4.1 MARKET DEFINITION
  • 17.4.2 MARKET OVERVIEW

18 APPENDIX

• 18.1 DISCUSSION GUIDE
• 18.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 18.3 CUSTOMIZATION OPTIONS
• 18.4 RELATED REPORTS
• 18.5 AUTHOR DETAILS